

2024-2029 Australia Tumor Markers Testing Market - High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers - 2024 Supplier Shares and Strategies, 2024-2029 Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers, Market Barriers and Risks

<https://marketpublishers.com/r/2AEDC66D83A7EN.html>

Date: December 2024

Pages: 0

Price: US\$ 2,500.00 (Single User License)

ID: 2AEDC66D83A7EN

Abstracts

This new report from LeadingMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the

rapid market expansion.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as: ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Partial Table of Contents

Introduction

Market Overview

Major Product Development Opportunities

Design Criteria for New Products

Alternative Market Penetration Strategies

Potential Market Entry Barriers and Risks

Major Current and Emerging Diagnostic Tests

Instrumentation Review and Market Needs

Current and Emerging Technologies

Market Size, Supplier Shares, Test Volume and Sales Segment Forecasts

Competitive Profiles and Strategies

Contents

- I. Introduction
- II. Worldwide Market Overview
- III. Major Product Development Opportunities
 - A. Reagent Kits and Test Systems/Panels
 - B. Instrumentation
 - C. Computers, Software and Automation
 - D. Auxiliary Products
- IV. Design Criteria for Decentralized Testing Products
- V. Alternative Market Penetration Strategies
 - A. Internal Development
 - B. Collaborative Arrangements
 - C. University Contracts
 - D. Distribution Strategies
- VI. Potential Market Entry Barriers and Risks
 - A. Market Maturity
 - B. Cost Containment
 - C. Competition
 - D. Technological Edge and Limitations
 - E. Patent Protection
 - F. Regulatory Constraints
 - G. Decentralized Testing Market Challenges
- VII. Worldwide Market and Technology Overview
 - A. Cancer Statistics and Etiology
 - 1. Breast Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer
 - 5. Stomach Cancer
 - 6. Leukemia
 - 7. Lymphoma
 - 8. Oral Cancer
 - 9. Skin Cancer
 - 10. Uterine Cancer
 - 11. Ovarian Cancer
 - 12. Bladder Cancer
- Table of Contents (continued)
- B. Major Current and Emerging Cancer Diagnostic Tests

1. Introduction
2. Tumor Marker Classification
3. ACTH
4. Alpha-Fetoprotein (AFP)
5. Beta-2 Microglobulin
6. CA 15-3/27.29
7. CA 19-9
8. CA-125
9. Calcitonin
10. Carcinoembryonic Antigen (CEA)
11. Estrogen and Progesterone Receptors
12. Ferritin
13. Gastrin
14. Human Chorionic Gonadotropin (HCG)
15. Insulin
16. NSE
17. Occult Blood
18. PAP Smear/HPV
19. Prostatic Acid Phosphatase (PAP)
20. Prostate-Specific Antigen (PSA)
21. Squamous Cell Carcinoma Antigen (SCC)
22. T and B Lymphocytes
23. TdT
24. Thyroglobulin
25. Tissue Polypeptide Antigen (TPA)
26. Biochemical Tumor Markers
27. Oncogenes
 - Abl/abl-bcr
 - AIB1
 - BCL-2
 - BRCA1
 - CD44
 - C-fos
 - C-myb
 - C-myc
 - CYP-17
 - Erb-B
 - HPC1
 - N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Table of Contents (continued)

Sis

Src and others

28. Polypeptide Growth Factors

Basic Fibroblast Growth Factor

Beta-TGF

Cachectin (TNT)

Calmodulin

ECFR

Nerve Growth Factor (NGF)

Epidermal Growth Factor (EGF)

Ornithine Decarboxylase

Transferrin

Transforming Growth Factor-Alpha

29. Ectopic Hormones

30. Colony Stimulating Factors

31. Lymphokines

Alpha-Interferon

B Cell Growth Factors

B Cell Growth Factor (BCGF)

Gamma-Interferon

Interleukin-1 (IL-1)

Macrophage Activating Factor

32. Immunohistochemical Stains

33. Emerging Tumor Markers

N-Acetylglucosamine

Actin

Alpha-Actin

Antineuronal Antibodies

7B2

B72.3

Bax

BCD-F9
BLCA-4
Blood Group Antigens A,B,H
CA 50
CA 72-4/TAG-72
CA 195
CA-242
CA-549
CAM 26
CAR-3
Cathepsin-D
Chromogranin A and B
Cluster 1 Antigen
Cluster-5/5A Antigen
CTA
CU18
DR-70
Table of Contents (continued)
DU-PAN-2
Endometrial Bleeding Associated F

I would like to order

Product name: 2024-2029 Australia Tumor Markers Testing Market - High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers - 2024 Supplier Shares and Strategies, 2024-2029 Volume and Sales Segment Forecasts for Major Tumor Markers, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers, Market Barriers and Risks

Product link: <https://marketpublishers.com/r/2AEDC66D83A7EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2AEDC66D83A7EN.html>